An improved procedure for the synthesis of nucleoside phosphoramidates

Organic Process Research and Development

Volumn 6, Issue 6, 2002, Pages 819-822

  Lehsten, Danielle M ^a   Baehr, David N ^b   Lobl, Thomas J ^a   Vaino, Andrew R ^a  

^a NewBiotics Inc   (United States)

^b REGIS TECHNOLOGIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXY 5' PHENYL (METHOXYALANYL)PHOSPHATE URIDINE; NB 1011; ORGANOPHOSPHATE; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ABSORPTION; CONFERENCE PAPER; DRUG PURITY; DRUG SYNTHESIS; ENZYME ACTIVITY; FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TEMPERATURE DEPENDENCE;

EID: 0036859895     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op025562c     Document Type: Conference Paper

References (20)

1. (a) McGuigan, C.; Pathirana, R. N.; Mahmood, N.; Devine, K. G.; Hay, A. J. Antiviral Res. 1992, 17, 311.
2. (b) McGuigan, C.; Cahard, D.; Sheeka, H.-M.; De Clercq, E.; Balzarini, J. Bioorg. Med. Chem. Lett. 1996, 6, 2521.
3. McGuigan, C.; Sutton, P. W.; Carhard, D.; Tumer, K.; O'Leary, G.; Wang, Y.; Gumbleton, M.; De Clerq, E.; Balzarini, J. Antiviral Chem. Chemother. 1998, 9, 473.
4. The existence of this cyclic intermediate is only postulated as its observation has not been reported in the literature, presumably due to the rapidity of its decomposition to the amino acyl phosphoramidate.
5. (a) Holzer, M. E.; Burrow, D. J.; Smith, R. A. Biochim. Biophys. Acta, 1962, 56, 491.
6. (b) Nishino, M.; Tsujimura, S.; Kuba, M.; Kumon, A. Arch. Biochem. Biophys. 1994, 312, 101.
7. Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; Velazquez, S.; McGuigan, C.; De Clercq, E.; Balzarini, J. Mol. Pharmacol. 1999, 56, 593.
8. (a) McGuigan, C.; Bellevergue, P.; Sheeka, H.; Mahmood, N.; Hay, A. J. FEBS Lett, 1994, 351, 11.
9. (b) Egron, D.; Lefebvre, I.; Périgaud, C.; Beltran, T.; Pompon, A.; Gosselin, G.; Aubertin, A.-M.; Imbach, J.-L. Bioorg. Med. Chem. Lett. 1998, 8, 1045.
10. The use of L-alanine as amino acid has been reported to be optimum for unveiling the phosphate functionality, at least for certain cell lines: McGuigan, C.; Tsang, H.-W.; Cahard, D.; Turner, S.; Velaquez, S.; Salgado, A.; Bodois, L.; Naesens, L.; De Clercq, E.; Balzarini, J. Antiviral Res. 1997, 35, 195.
11. (a) Siddiqui, A. Q.; Ballatore, C.; McGuigan, C.; De Clercq, E.; Balzarini, J. J. Med. Chem. 1999, 42, 393.
12. (b) Manfredini, S.; Baraldi, P. G.; Durini, E.; Vertuani, S.; Balzarini, J.; De Clercq, E.; Karlsson, A.; Buzzoni, V.; Thelander, L. J. Med. Chem. 1999, 42, 3243.
13. Kumar, D.; Kanz, B.; Mamiya, B. M.; Kern, J. T.; Kerwin, S. M. Tetrahedron Lett. 2001, 42, 565.
14. A report describing a series of phosphoramidate derivatives has recently appeared: Harris, S. A.; McGuigan, C.; Andrei, G.; De Clercq, E.; Balzarini, J. Antiviral Chem. Chemother. 2002, 12, 293.
15. (a) Lackey, D. B.; Groziak, M. P.; Sergeeva, M.; Beryt, M.; Boyer, C.; Stroud, R. M.; Sayre, P.; Park, J. W.; Johnston, P.; Slamon, D.; Shepard, H. M.; Pegram, M. Biochem. Pharmacol. 2001, 61, 179.
16. (b) Li, Q.; Boyer, C.; Lee, J. Y.; Shepard, M. H. Mol. Pharmacol. 2001, 59, 446. (c) Shepard, H. M. U.S. Patent 6,245,750.
17. (c) Shepard, H. M. U.S. Patent 6,245,750.
18. The report (ref 9) describes the major impurity as being the 3′,5′-di-acylated phosphoramidate.
19. Jones, A. S.; Verhelst, G.; Walker, R. T. Tetrahedron Lett. 1979, 45, 4415.
20. 2:MeOH.